 Evoke Pharma, Inc. EVOK, a specialty pharmaceutical company focused on treatments for gastrointestinal GI diseases, today announced that it has resubmitted its 505b2 New Drug Application NDA to the U.S. Food and Drug Administration FDA for GimotiTM, the companys nasal spray product candidate for the relief of symptoms in adult women with acute and recurrent diabetic gastroparesis. The NDA for Gimoti was resubmitted based on feedback received during the Type A meeting with FDA in July 2019. 